Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes

INTRODUCTION: Elderly people (≥65 years) with type 2 diabetes mellitus (T2DM) are becoming increasingly prevalent, notably in Japan. As cardiovascular (CV) risk increases with age and sodium–glucose cotransporter-2 (SGLT2) inhibitors reduce CV risk, elderly patients with T2DM are increasingly likely...

Descripción completa

Detalles Bibliográficos
Autores principales: Yabe, Daisuke, Shiki, Kosuke, Suzaki, Keiko, Meinicke, Thomas, Kotobuki, Yutaro, Nishida, Kenichiro, Clark, Douglas, Yasui, Atsutaka, Seino, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8031078/
https://www.ncbi.nlm.nih.gov/pubmed/33827843
http://dx.doi.org/10.1136/bmjopen-2020-045844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8031078/
https://www.ncbi.nlm.nih.gov/pubmed/33827843
http://dx.doi.org/10.1136/bmjopen-2020-045844

Ejemplares similares